Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	DNA topoisomerase type I (single strand cut, ATP-independent) activity	TOP1MT TOP1	4.79e-05	4	57	2	GO:0003917
GeneOntologyMolecularFunction	single-stranded DNA 3'-5' DNA exonuclease activity	POLE POLG	1.19e-04	6	57	2	GO:0008310
GeneOntologyMolecularFunction	DNA topoisomerase activity	TOP1MT TOP1	2.22e-04	8	57	2	GO:0003916
GeneOntologyMolecularFunction	single-stranded DNA exodeoxyribonuclease activity	POLE POLG	3.55e-04	10	57	2	GO:0008297
GeneOntologyMolecularFunction	GDP phosphatase activity	GBP2 GBP3	5.19e-04	12	57	2	GO:0004382
GeneOntologyMolecularFunction	calcium-activated potassium channel activity	CCT8L2 PKD2L1	7.13e-04	14	57	2	GO:0015269
GeneOntologyMolecularFunction	3'-5'-DNA exonuclease activity	POLE POLG	9.36e-04	16	57	2	GO:0008296
GeneOntologyMolecularFunction	cytokine binding	A2M GBP2 GBP3 IL6ST	1.05e-03	157	57	4	GO:0019955
GeneOntologyMolecularFunction	nucleoside diphosphate phosphatase activity	GBP2 GBP3	1.47e-03	20	57	2	GO:0017110
GeneOntologyMolecularFunction	DNA exonuclease activity, producing 5'-phosphomonoesters	POLE POLG	2.30e-03	25	57	2	GO:0016895
GeneOntologyMolecularFunction	DNA-directed DNA polymerase activity	POLE POLG	2.30e-03	25	57	2	GO:0003887
GeneOntologyMolecularFunction	catalytic activity, acting on a nucleic acid	EPRS1 ALKBH8 POLE POLG MARF1 TOP1MT TOP1	2.31e-03	645	57	7	GO:0140640
GeneOntologyMolecularFunction	DNA exonuclease activity	POLE POLG	2.49e-03	26	57	2	GO:0004529
GeneOntologyMolecularFunction	calcium-activated cation channel activity	CCT8L2 PKD2L1	2.68e-03	27	57	2	GO:0005227
GeneOntologyMolecularFunction	dioxygenase activity	ALKBH8 PIR KDM4E	2.77e-03	98	57	3	GO:0051213
GeneOntologyMolecularFunction	retinoic acid binding	UGT2B15 UGT2B17	2.89e-03	28	57	2	GO:0001972
GeneOntologyMolecularFunction	alpha-actinin binding	DAG1 PKD2L1	3.53e-03	31	57	2	GO:0051393
GeneOntologyMolecularFunction	monoatomic ion-gated channel activity	CCT8L2 PKD2L1	3.53e-03	31	57	2	GO:0022839
GeneOntologyMolecularFunction	spectrin binding	GBP2 GBP3	4.24e-03	34	57	2	GO:0030507
GeneOntologyMolecularFunction	glucuronosyltransferase activity	UGT2B15 UGT2B17	4.48e-03	35	57	2	GO:0015020
GeneOntologyMolecularFunction	DNA polymerase activity	POLE POLG	5.27e-03	38	57	2	GO:0034061
GeneOntologyBiologicalProcess	DNA replication proofreading	POLE POLG	2.33e-05	3	58	2	GO:0045004
GeneOntologyBiologicalProcess	positive regulation of AIM2 inflammasome complex assembly	GBP2 GBP3	4.65e-05	4	58	2	GO:0140973
GeneOntologyCellularComponent	host cell part	GBP2 GBP3	1.13e-04	6	58	2	GO:0033643
GeneOntologyCellularComponent	host intracellular part	GBP2 GBP3	1.13e-04	6	58	2	GO:0033646
GeneOntologyCellularComponent	host cell cytoplasm part	GBP2 GBP3	1.13e-04	6	58	2	GO:0033655
GeneOntologyCellularComponent	symbiont-containing vacuole	GBP2 GBP3	1.13e-04	6	58	2	GO:0020003
GeneOntologyCellularComponent	symbiont-containing vacuole membrane	GBP2 GBP3	1.13e-04	6	58	2	GO:0020005
GeneOntologyCellularComponent	host intracellular region	GBP2 GBP3	1.13e-04	6	58	2	GO:0043656
GeneOntologyCellularComponent	host cell cytoplasm	GBP2 GBP3	1.13e-04	6	58	2	GO:0030430
GeneOntologyCellularComponent	symbiont cell surface	GBP2 GBP3	2.10e-04	8	58	2	GO:0106139
GeneOntologyCellularComponent	other organism part	GBP2 GBP3	2.69e-04	9	58	2	GO:0044217
GeneOntologyCellularComponent	host cellular component	GBP2 GBP3	7.76e-04	15	58	2	GO:0018995
GeneOntologyCellularComponent	DNA polymerase complex	POLE POLG	1.39e-03	20	58	2	GO:0042575
Domain	DNA_brk_join_enz	TOP1MT TOP1	8.51e-06	2	55	2	IPR011010
Domain	Topoisom_I_N	TOP1MT TOP1	8.51e-06	2	55	2	PF02919
Domain	TopoI_cat_a/b-sub_euk	TOP1MT TOP1	8.51e-06	2	55	2	IPR014727
Domain	TOPEUc	TOP1MT TOP1	8.51e-06	2	55	2	SM00435
Domain	TopoI	TOP1MT TOP1	8.51e-06	2	55	2	IPR001631
Domain	TopoI_cat_a-hlx-sub_euk	TOP1MT TOP1	8.51e-06	2	55	2	IPR014711
Domain	TopoI_cat_euk	TOP1MT TOP1	8.51e-06	2	55	2	IPR013500
Domain	TopoI_C_dom	TOP1MT TOP1	8.51e-06	2	55	2	IPR025834
Domain	-	TOP1MT TOP1	8.51e-06	2	55	2	1.10.132.10
Domain	TopoI_DNA-bd_euk	TOP1MT TOP1	8.51e-06	2	55	2	IPR008336
Domain	-	TOP1MT TOP1	8.51e-06	2	55	2	3.90.15.10
Domain	Topoisom_I	TOP1MT TOP1	8.51e-06	2	55	2	PF01028
Domain	TopoI_AS	TOP1MT TOP1	8.51e-06	2	55	2	IPR018521
Domain	DNA_topo_domain1	TOP1MT TOP1	8.51e-06	2	55	2	IPR013034
Domain	TopoI_DNA-bd_mixed-a/b_euk	TOP1MT TOP1	8.51e-06	2	55	2	IPR013030
Domain	-	TOP1MT TOP1	8.51e-06	2	55	2	1.10.10.41
Domain	TopoI_euk	TOP1MT TOP1	8.51e-06	2	55	2	IPR013499
Domain	-	TOP1MT TOP1	8.51e-06	2	55	2	2.170.11.10
Domain	Topo_C_assoc	TOP1MT TOP1	8.51e-06	2	55	2	PF14370
Domain	TOPOISOMERASE_I_EUK	TOP1MT TOP1	8.51e-06	2	55	2	PS00176
Domain	GBP_C	GBP2 GBP3	3.77e-04	10	55	2	PF02841
Domain	G_GB1_RHD3_dom	GBP2 GBP3	4.60e-04	11	55	2	IPR030386
Domain	Guanylate-bd_C	GBP2 GBP3	4.60e-04	11	55	2	IPR003191
Domain	GBP	GBP2 GBP3	4.60e-04	11	55	2	PF02263
Domain	Guanylate-bd_N	GBP2 GBP3	4.60e-04	11	55	2	IPR015894
Domain	G_GB1_RHD3	GBP2 GBP3	4.60e-04	11	55	2	PS51715
Domain	fn3	CNTN4 ROS1 MYBPHL IL6ST	1.32e-03	162	55	4	PF00041
Domain	UDPGT	UGT2B15 UGT2B17	1.72e-03	21	55	2	PF00201
Domain	UDPGT	UGT2B15 UGT2B17	1.72e-03	21	55	2	PS00375
Domain	UDP_glucos_trans	UGT2B15 UGT2B17	1.72e-03	21	55	2	IPR002213
Domain	FN3	CNTN4 ROS1 MYBPHL IL6ST	2.14e-03	185	55	4	SM00060
Domain	FN3	CNTN4 ROS1 MYBPHL IL6ST	2.79e-03	199	55	4	PS50853
Domain	-	CNTN4 HMCN1 DAG1 ROS1 MYBPHL IL6ST VSTM1	3.18e-03	663	55	7	2.60.40.10
Domain	FN3_dom	CNTN4 ROS1 MYBPHL IL6ST	3.33e-03	209	55	4	IPR003961
Domain	Ig-like_fold	CNTN4 HMCN1 DAG1 ROS1 MYBPHL IL6ST VSTM1	4.49e-03	706	55	7	IPR013783
Pathway	REACTOME_REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS	DAG1 USP33	1.47e-04	7	38	2	MM15593
Pathway	KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM	EPRS1 UGT2B15 UGT2B17	1.79e-04	41	38	3	M7399
Pathway	REACTOME_TRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL	EPRS1 ALKBH8 ADAT1	2.07e-04	43	38	3	M27602
Pubmed	Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism.	TOP1MT TOP1	2.93e-06	2	60	2	22911747
Pubmed	Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells.	UGT2B15 UGT2B17	2.93e-06	2	60	2	32660355
Pubmed	The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence.	UGT2B15 UGT2B17	2.93e-06	2	60	2	1909870
Pubmed	Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.	UGT2B15 UGT2B17	2.93e-06	2	60	2	24121496
Pubmed	Mouse UDP glucuronosyltransferase. cDNA and complete amino acid sequence and regulation.	UGT2B15 UGT2B17	2.93e-06	2	60	2	3117546
Pubmed	Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study.	UGT2B15 UGT2B17	2.93e-06	2	60	2	24267955
Pubmed	Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.	UGT2B15 UGT2B17	2.93e-06	2	60	2	22170718
Pubmed	Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.	TOP1MT TOP1	2.93e-06	2	60	2	26305952
Pubmed	Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA.	TOP1MT TOP1	2.93e-06	2	60	2	18826252
Pubmed	Localization of UDP glucuronosyltransferase gene(s) on mouse chromosome 5.	UGT2B15 UGT2B17	2.93e-06	2	60	2	3105095
Pubmed	UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.	UGT2B15 UGT2B17	2.93e-06	2	60	2	17848572
Pubmed	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.	UGT2B15 UGT2B17	2.93e-06	2	60	2	27496708
Pubmed	Comprehensive Characterization of Mouse UDP-Glucuronosyltransferase (Ugt) Belonging to the Ugt2b Subfamily: Identification of Ugt2b36 as the Predominant Isoform Involved in Morphine Glucuronidation.	UGT2B15 UGT2B17	2.93e-06	2	60	2	28228532
Pubmed	Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.	UGT2B15 UGT2B17	2.93e-06	2	60	2	15666817
Pubmed	The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.	UGT2B15 UGT2B17	2.93e-06	2	60	2	17698910
Pubmed	Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.	UGT2B15 UGT2B17	8.77e-06	3	60	2	19572376
Pubmed	Guanylate binding proteins facilitate caspase-11-dependent pyroptosis in response to type 3 secretion system-negative Pseudomonas aeruginosa.	GBP2 GBP3	8.77e-06	3	60	2	30062052
Pubmed	Guanylate binding proteins enable rapid activation of canonical and noncanonical inflammasomes in Chlamydia-infected macrophages.	GBP2 GBP3	8.77e-06	3	60	2	26416908
Pubmed	Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.	UGT2B15 UGT2B17	8.77e-06	3	60	2	26163549
Pubmed	Guanylate-binding protein 2 orchestrates innate immune responses against murine norovirus and is antagonized by the viral protein NS7.	GBP2 GBP3	8.77e-06	3	60	2	32354743
Pubmed	GTPase properties of the interferon-induced human guanylate-binding protein 2.	GBP2 GBP3	8.77e-06	3	60	2	8706832
Pubmed	Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.	UGT2B15 UGT2B17	8.77e-06	3	60	2	20736324
Pubmed	Guanylate binding proteins contained in the murine chromosome 3 are important to control mycobacterial infection.	GBP2 GBP3	8.77e-06	3	60	2	32620042
Pubmed	[Guanylate-binding protein 2 regulates the maturation of mouse dendritic cells induced by β-glucan].	GBP2 GBP3	8.77e-06	3	60	2	29089068
Pubmed	Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.	UGT2B15 UGT2B17	8.77e-06	3	60	2	26385605
Pubmed	Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.	UGT2B15 UGT2B17	8.77e-06	3	60	2	28882566
Pubmed	Length-independent telomere damage drives post-mitotic cardiomyocyte senescence.	POLG CAT	8.77e-06	3	60	2	30737259
Pubmed	Murine guanylate binding protein 2 (mGBP2) controls Toxoplasma gondii replication.	GBP2 GBP3	8.77e-06	3	60	2	23248289
Pubmed	Interferon-induced guanylate-binding proteins lack an N(T)KXD consensus motif and bind GMP in addition to GDP and GTP.	GBP2 GBP3	8.77e-06	3	60	2	1715024
Pubmed	Two families of GTPases dominate the complex cellular response to IFN-gamma.	GBP2 GBP3	8.77e-06	3	60	2	9862701
Pubmed	The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation.	GBP2 GBP3	8.77e-06	3	60	2	11726669
Pubmed	GBP2 inhibits pathological angiogenesis in the retina via the AKT/mTOR/VEGFA axis.	GBP2 GBP3	8.77e-06	3	60	2	38636926
Pubmed	Domain motions, dimerization, and membrane interactions of the murine guanylate binding protein 2.	GBP2 GBP3	8.77e-06	3	60	2	36639389
Pubmed	Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.	UGT2B15 UGT2B17	8.77e-06	3	60	2	17988216
Pubmed	Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus.	UGT2B15 UGT2B17	8.77e-06	3	60	2	23223495
Pubmed	The interferon-induced GTPase, mGBP-2, confers resistance to paclitaxel-induced cytotoxicity without inhibiting multinucleation.	GBP2 GBP3	8.77e-06	3	60	2	16914101
Pubmed	Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.	ROS1 IL6ST	8.77e-06	3	60	2	31907296
Pubmed	Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.	UGT2B15 UGT2B17	8.77e-06	3	60	2	18302198
Pubmed	The GTPase activity of murine guanylate-binding protein 2 (mGBP2) controls the intracellular localization and recruitment to the parasitophorous vacuole of Toxoplasma gondii.	GBP2 GBP3	8.77e-06	3	60	2	22730319
Pubmed	The nuclear receptor Shp regulates morphine withdrawal syndrome via modulation of Ugt2b expression in mice.	UGT2B15 UGT2B17	8.77e-06	3	60	2	30689982
Pubmed	Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain.	GBP2 GBP3	8.77e-06	3	60	2	15717119
Pubmed	Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.	GBP2 GBP3	8.77e-06	3	60	2	35383115
Pubmed	Role of GTP binding, isoprenylation, and the C-terminal α-helices in the inhibition of cell spreading by the interferon-induced GTPase, mouse guanylate-binding protein-2.	GBP2 GBP3	8.77e-06	3	60	2	20950129
Pubmed	Interferon regulatory factor 1 is required for mouse Gbp gene activation by gamma interferon.	GBP2 GBP3	1.75e-05	4	60	2	7823961
Pubmed	Dnmt1/Tet2-mediated changes in Cmip methylation regulate the development of nonalcoholic fatty liver disease by controlling the Gbp2-Pparγ-CD36 axis.	GBP2 GBP3	1.75e-05	4	60	2	36609599
Pubmed	Genomic organization and chromosomal localization of a new member of the murine interferon-induced guanylate-binding protein family.	GBP2 GBP3	1.75e-05	4	60	2	10386861
Pubmed	Guanylate-binding protein-5 is involved in inflammasome activation by bacterial DNA but only the cooperation of multiple GBPs accounts for control of Brucella abortus infection.	GBP2 GBP3	1.75e-05	4	60	2	38404575
Pubmed	Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.	UGT2B15 UGT2B17	1.75e-05	4	60	2	18281521
Pubmed	Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.	UGT2B15 UGT2B17	1.75e-05	4	60	2	26176234
Pubmed	cDNA for the beta 1 subunit of guanyl nucleotide-binding regulatory proteins from mouse adrenal glands.	GBP2 GBP3	1.75e-05	4	60	2	8917111
Pubmed	The Furin Protease Dependence and Antiviral GBP2 Sensitivity of Murine Leukemia Virus Infection Are Determined by the Amino Acid Sequence at the Envelope Glycoprotein Cleavage Site.	GBP2 GBP3	1.75e-05	4	60	2	39337476
Pubmed	TCR Affinity Biases Th Cell Differentiation by Regulating CD25, Eef1e1, and Gbp2.	GBP2 GBP3	2.92e-05	5	60	2	30858199
Pubmed	Murine GBP-5, a new member of the murine guanylate-binding protein family, is coordinately regulated with other GBPs in vivo and in vitro.	GBP2 GBP3	2.92e-05	5	60	2	12396730
Pubmed	Unique features of different members of the human guanylate-binding protein family.	GBP2 GBP3	2.92e-05	5	60	2	17266443
Pubmed	Intracellular trafficking of guanylate-binding proteins is regulated by heterodimerization in a hierarchical manner.	GBP2 GBP3	2.92e-05	5	60	2	21151871
Pubmed	Essential Role of mGBP7 for Survival of Toxoplasma gondii Infection.	GBP2 GBP3	2.92e-05	5	60	2	31964735
Pubmed	Murine GBP-2: a new IFN-gamma-induced member of the GBP family of GTPases isolated from macrophages.	GBP2 GBP3	2.92e-05	5	60	2	9858320
Pubmed	Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene.	GBP2 GBP3	4.37e-05	6	60	2	17293456
Pubmed	Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer.	UGT2B15 UGT2B17	4.37e-05	6	60	2	21365123
Pubmed	Immunity-related GTPase M (IRGM) proteins influence the localization of guanylate-binding protein 2 (GBP2) by modulating macroautophagy.	GBP2 GBP3	4.37e-05	6	60	2	21757726
Pubmed	A High-Density Human Mitochondrial Proximity Interaction Network.	DIP2A UTP18 MYO1D POLE POLG RNF213 CAT RBM28 LARP1B TOP1 USP33	4.42e-05	1496	60	11	32877691
Pubmed	The interferon-gamma-induced murine guanylate-binding protein-2 inhibits rac activation during cell spreading on fibronectin and after platelet-derived growth factor treatment: role for phosphatidylinositol 3-kinase.	GBP2 GBP3	6.11e-05	7	60	2	20505078
Pubmed	TRIF signaling is required for caspase-11-dependent immune responses and lethality in sepsis.	GBP2 GBP3	6.11e-05	7	60	2	30587103
Pubmed	Weak activity of UDP-glucuronosyltransferase toward Bisphenol analogs in mouse perinatal development.	UGT2B15 UGT2B17	6.11e-05	7	60	2	26074487
Pubmed	The interferon-gamma-induced GTPase, mGBP-2, inhibits tumor necrosis factor alpha (TNF-alpha) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-kappaB and Rac protein.	GBP2 GBP3	6.11e-05	7	60	2	21502320
Pubmed	Hetero-oligomer formation of mouse UDP-glucuronosyltransferase (UGT) 2b1 and 1a1 results in the gain of glucuronidation activity towards morphine, an activity which is absent in homo-oligomers of either UGT.	UGT2B15 UGT2B17	8.14e-05	8	60	2	32093886
Pubmed	Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry.	UGT2B15 UGT2B17	8.14e-05	8	60	2	22579593
Pubmed	In silico genomic analysis of the human and murine guanylate-binding protein (GBP) gene clusters.	GBP2 GBP3	8.14e-05	8	60	2	16689661
Pubmed	The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases.	UGT2B15 UGT2B17	8.14e-05	8	60	2	18719240
Pubmed	Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.	UGT2B15 UGT2B17	8.14e-05	8	60	2	20142249
Pubmed	Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases.	GBP2 GBP3	1.05e-04	9	60	2	24739961
Pubmed	Osteoclast fusion and bone loss are restricted by interferon inducible guanylate binding proteins.	GBP2 GBP3	1.05e-04	9	60	2	33479228
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	CCDC88C DIP2A SPG7 CCDC34 POLE POLG IRS1 GTF2IRD1 ADAT1	1.10e-04	1105	60	9	35748872
Pubmed	Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma.	IRS1 IL6ST	1.31e-04	10	60	2	19124510
Pubmed	Transcriptomic analysis brings new insight into the biological role of the prion protein during mouse embryogenesis.	A2M PRAP1	1.31e-04	10	60	2	21858045
Pubmed	Gβ2 Regulates the Multipolar-Bipolar Transition of Newborn Neurons in the Developing Neocortex.	GBP2 GBP3	1.31e-04	10	60	2	28334111
Pubmed	Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS.	GBP2 GBP3	1.59e-04	11	60	2	24715728
Pubmed	IRGB10 Liberates Bacterial Ligands for Sensing by the AIM2 and Caspase-11-NLRP3 Inflammasomes.	GBP2 GBP3	1.59e-04	11	60	2	27693356
Pubmed	Extensive characterization of IFN-induced GTPases mGBP1 to mGBP10 involved in host defense.	GBP2 GBP3	1.59e-04	11	60	2	18025219
Pubmed	Pathogen-selective killing by guanylate-binding proteins as a molecular mechanism leading to inflammasome signaling.	GBP2 GBP3	1.91e-04	12	60	2	35906252
Pubmed	LPS targets host guanylate-binding proteins to the bacterial outer membrane for non-canonical inflammasome activation.	GBP2 GBP3	1.91e-04	12	60	2	29459437
Pubmed	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.	UGT2B15 UGT2B17	1.91e-04	12	60	2	20308471
Pubmed	Fv2 encodes a truncated form of the Stk receptor tyrosine kinase.	UBA7 DAG1	2.26e-04	13	60	2	10508511
Pubmed	Proteomic analysis of the mouse liver mitochondrial inner membrane.	POLG UGT2B15 UGT2B17 FAHD1	2.42e-04	175	60	4	12865426
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	A2M NUSAP1 EPRS1 UTP18 MYO1D BAZ1B CAT RBM28 TOP1	2.88e-04	1257	60	9	36526897
Pubmed	Mapping of quantitative trait loci determining NK cell-mediated resistance to MHC class I-deficient bone marrow grafts in perforin-deficient mice.	GBP2 GBP3	3.03e-04	15	60	2	17114464
Pubmed	Guanylate-binding proteins promote activation of the AIM2 inflammasome during infection with Francisella novicida.	GBP2 GBP3	3.03e-04	15	60	2	25774716
Pubmed	Association analysis of 3p21 with Crohn's disease in a New Zealand population.	UBA7 DAG1	3.91e-04	17	60	2	20307617
Pubmed	The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection.	GBP2 GBP3	3.91e-04	17	60	2	25774715
Pubmed	The macrophage IRF8/IRF1 regulome is required for protection against infections and is associated with chronic inflammation.	GBP2 GBP3	4.40e-04	18	60	2	27001747
Pubmed	Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86.	NUSAP1 UTP18	4.40e-04	18	60	2	35411049
Pubmed	A family of IFN-γ-inducible 65-kD GTPases protects against bacterial infection.	GBP2 GBP3	4.91e-04	19	60	2	21551061
Pubmed	USP53 plays an antitumor role in hepatocellular carcinoma through deubiquitination of cytochrome c.	EPRS1 BAZ1B RBM28	5.15e-04	90	60	3	35654790
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	NUSAP1 EPRS1 ALKBH8 SPG7 POLG DAG1 BAZ1B RBM28	5.28e-04	1084	60	8	11544199
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	A2M NUSAP1 EPRS1 PIGK MARF1 ROS1 RBM28 LARP1B TOP1	5.41e-04	1371	60	9	36244648
Pubmed	Interferon inducible GBPs restrict Burkholderia thailandensis motility induced cell-cell fusion.	GBP2 GBP3	5.45e-04	20	60	2	32150572
Pubmed	Identification of novel human Cdt1-binding proteins by a proteomics approach: proteolytic regulation by APC/CCdh1.	BAZ1B TOP1	5.45e-04	20	60	2	18162579
Pubmed	An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome.	GBP2 GBP3	6.02e-04	21	60	2	19158679
Pubmed	Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.	MATK IRS1	6.61e-04	22	60	2	22305495
Pubmed	NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency.	BAZ1B TOP1MT TOP1	7.64e-04	103	60	3	32744500
Cytoband	4q13	UGT2B15 UGT2B17	1.74e-04	15	60	2	4q13
Cytoband	1p22.2	GBP2 GBP3	6.21e-04	28	60	2	1p22.2
Cytoband	3p21	UBA7 DAG1	8.64e-04	33	60	2	3p21
GeneFamily	Fibronectin type III domain containing	CNTN4 PTPRQ ROS1 MYBPHL IL6ST	2.61e-05	160	40	5	555
GeneFamily	Topoisomerases	TOP1MT TOP1	7.12e-05	6	40	2	1050
GeneFamily	DNA polymerases	POLE POLG	1.17e-03	23	40	2	535
GeneFamily	UDP glucuronosyltransferases	UGT2B15 UGT2B17	2.27e-03	32	40	2	363
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	CNTN4 HMCN1 MYBPHL	5.38e-03	161	40	3	593
Coexpression	WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP	UBA7 UGT2B15 UGT2B17 GBP2 GBP3 GAST	3.55e-08	84	59	6	MM1049
Coexpression	GSE17721_0.5H_VS_4H_POLYIC_BMDC_DN	MYO1D GBP2 IRF2 GAST ADAT1 IL6ST	5.89e-06	200	59	6	M4091
Coexpression	MURARO_PANCREAS_DUCTAL_CELL	A2M EPRS1 DAG1 UGT2B15 GBP2 RNF213 GBP3 CAT ATP13A3 FAHD1 TOP1 IL6ST	2.25e-05	1276	59	12	M39173
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#3	NUSAP1 BAZ1B RNF213 CAT FAHD1 GTF2IRD1 ZFP69 TOP1	2.16e-05	432	58	8	Facebase_RNAseq_e10.5_Maxillary Arch_1000_K3
ToppCell	T_cells-ISG-high_CD4+_T_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	UBA7 GBP2 RNF213 GBP3 IRS1 TOP1 IL6ST	6.37e-09	188	60	7	6f8946d4710f6e32c937213f99b790b098b8819c
ToppCell	T_cells-ISG-high_CD4+_T_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	UBA7 GBP2 RNF213 GBP3 IRS1 TOP1	1.53e-07	179	60	6	af35ef8a7768cee0c2af0590e5bec35cee6a4714
ToppCell	COVID-19_Severe-Lymphoid_T/NK-gd_T\|COVID-19_Severe / Disease group, lineage and cell class	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.53e-07	195	60	6	9990440bda7fac5d00ef80444fab07459be625e1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.61e-07	196	60	6	418e8e0a51c5cb60e3b903e7d2d800dc8b9f3d5c
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.61e-07	196	60	6	581fc8c8d42005aacd7b401a2c9d1fc331fb4af7
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.61e-07	196	60	6	6beaf0c2799424c59819b286fbb5c1a83d85e4d1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.61e-07	196	60	6	c35f2349dfe35baa845f790b9f31673dceac54c0
ToppCell	COVID_non-vent-Lymphocytic-T_cell-CD8+_Memory_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.69e-07	197	60	6	836061acd7f0d5de89b16f52ec679bdf09eac9db
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.93e-07	200	60	6	2bd8c35484fe6b0bc0f9314216786baaa97d1e95
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-T/NK-gd_T\|COVID-19_Severe / Disease, condition lineage and cell class	A2M CCDC88C DIP2A TTC16 MATK RNF213	2.93e-07	200	60	6	f72bc3f6606ae77fe1b0a972e35b3ce0727804d9
ToppCell	LV-13._Vascular_Smooth_Muscle\|LV / Chamber and Cluster_Paper	A2M CNTN4 MYO1D DOCK8 GBP2	3.45e-06	171	60	5	e99ecae66530d1ae09330cee408c8f3950b87e67
ToppCell	droplet-Heart-nan-24m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 TTC16 PIR IL6ST	5.62e-06	189	60	5	1137583e21d874c201c20581ba1995e2bfa3de59
ToppCell	droplet-Heart-nan-24m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 TTC16 PIR IL6ST	5.76e-06	190	60	5	7068754c29f63a331e2b6c54715f3b26f37ad32b
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_B-Plasma_cell\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NUSAP1 OSTC MYO1D LARP1B TOP1	5.91e-06	191	60	5	fca19f2719806f3dc2dd2add7252ab1198548f4d
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-Plasma_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	OSTC EPRS1 MYO1D UGT2B17 LARP1B	6.22e-06	193	60	5	1f50823bd7ef00500d9d81f0f5c2f6c940c4b1a6
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-Plasma_cell-B_c05-MZB1-XBP1\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	OSTC EPRS1 MYO1D UGT2B17 LARP1B	6.22e-06	193	60	5	b9c00df1b216eaa4283315713f1c9ef552d3d435
ToppCell	severe_COVID-19-CD4+_CTL\|World / disease group, cell group and cell class (v2)	CCDC88C DIP2A TTC16 MATK RNF213	6.38e-06	194	60	5	bdafc1173b7b8cde8714573fbeee5394a2484a5f
ToppCell	T_cells-GZMK+_T_cells\|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	A2M TTC16 MATK RNF213 ADAT1	6.54e-06	195	60	5	003ea7ddec6c1c98d2f6470bb51ebd97450eb936
ToppCell	healthy_donor-Lymphocytic-T_cell-CD8+_Memory_T_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	A2M CCDC88C TTC16 MATK RNF213	6.70e-06	196	60	5	af00c31612e4fe068e5fccae05368edba46bbd20
ToppCell	severe_COVID-19-CD4+_CTL\|severe_COVID-19 / disease group, cell group and cell class (v2)	CCDC88C DIP2A TTC16 MATK RNF213	6.87e-06	197	60	5	e51b7cd03b1450dc8601b4be0453b104d6a5f955
ToppCell	COVID_vent-Lymphocytic-T_cell-CD8+_Memory_T_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	CCDC88C DIP2A TTC16 MATK RNF213	6.87e-06	197	60	5	d4dfb3b561d0783cdbee4e8d27009ad81df695cb
ToppCell	Bronchial-NucSeq-Immune_Lymphocytic-T-T_CD8-CD8_CTL\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	A2M CCDC88C DOCK8 TTC16 RNF213	7.22e-06	199	60	5	eb188b0b457136b6ee485d3b3052baa30d9c0002
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_Tem-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	af43f6d0e03b77f5eca1762e7b2be1d244d47664
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-gd_T\|COVID-19_Mild / Disease, condition lineage and cell class	A2M CCDC88C TTC16 MATK RNF213	7.39e-06	200	60	5	6560753d3df2f87860b52052d4881aa45410f666
ToppCell	mild-CD8+_Tem\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	A2M CCDC88C TTC16 MATK RNF213	7.39e-06	200	60	5	d8aec4904c9420b8f9d7508658ba1e36c66cdfcc
ToppCell	remission-CD8+_Tem\|World / disease stage, cell group and cell class	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	0ebf0dda91fc7adb9ea69734ad9dcc65d0082c6d
ToppCell	COVID-19-COVID-19_Convalescent-Lymphocyte-T/NK-CD8+_Tem\|COVID-19_Convalescent / Disease, condition lineage and cell class	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	7c8a5465b478f430495942151c36020023d9bac9
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	63077e1f801f1c08bd339f5517f5781da240c04f
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_Tem\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	f0452dc1056b5ea492e61b20bb52815a5d2f705e
ToppCell	mild-gd_T\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	A2M CCDC88C TTC16 MATK RNF213	7.39e-06	200	60	5	109f673a4967ffa52270a0b4f818b3461288db44
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_Tem-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	024eafabb576bfb835452def941237a35eebb912
ToppCell	remission-CD8+_Tem\|remission / disease stage, cell group and cell class	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	f1e4b8fcb422727f665f22b48f34bee23f0fad52
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_Tem\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	64c2399c78e4ce0f05893d856bf90b1d3f5dba03
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	94d4f690bf5b87866c0840715396d360b1737d11
ToppCell	COVID-19_Convalescent-Lymphoid_T/NK-CD8+_Tem\|COVID-19_Convalescent / Disease group, lineage and cell class	CCDC88C DIP2A TTC16 MATK RNF213	7.39e-06	200	60	5	3f00839697183a1066548930b9ec3664b3568afc
ToppCell	facs-Lung-Endomucin-24m-Endothelial-Capillary_Type_1_Cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	POLE PTPRQ PKD2L1 ROS1	4.39e-05	145	60	4	96712c68ab759d7ade0d912581a1a7c25dc6def8
ToppCell	COVID-19_Moderate-multiplets\|World / disease group, cell group and cell class	CNTN4 DIP2A TTC16 RNF213	5.83e-05	156	60	4	afdc025fa75e7926b1cc182c4a33654a2186abb1
ToppCell	facs-Lung-24m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	POLE PTPRQ PKD2L1 ROS1	6.75e-05	162	60	4	bf886e22ff2a20353499004b53f25fb9e6574896
ToppCell	LV-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	A2M MYO1D DOCK8 GBP2	7.25e-05	165	60	4	f37fd95adc95d7753cf6e55ae819976513c7ec77
ToppCell	droplet-Lung-3m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l15\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DOCK8 MATK BAZ1B MYBPHL	7.25e-05	165	60	4	1d0f60bf47a40ac916f0fcb5532a968742a0edbb
ToppCell	PND14-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HMCN1 GBP2 PIR IL6ST	7.95e-05	169	60	4	58136b8a0bf2dab45c91a053ef7225ea49ccb871
ToppCell	PND14-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC-VEC_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HMCN1 GBP2 PIR IL6ST	7.95e-05	169	60	4	04c6ed38e1d1befba5ef5f37a3c1e045a0b163d6
ToppCell	390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0\|390C / Donor, Lineage, Cell class and subclass (all cells)	CCDC88C DIP2A TTC16 RNF213	8.32e-05	171	60	4	d6d8ea45b443d95f64720c9bc07d324148f5b239
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK-NK_G2M\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NUSAP1 CCDC34 POLE ZFP69	8.51e-05	172	60	4	dd9ba79e1542fe9fa2c319077d83dd3fc0158f46
ToppCell	Children_(3_yrs)-Immune-natural_killer_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	CCDC88C DIP2A TTC16 MATK	8.90e-05	174	60	4	33d6b81f31bfcb9c4b30206d88e20b9a94fba4a2
ToppCell	droplet-Limb_Muscle-MUSCLE-30m\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CCDC88C BAZ1B GBP2 GBP3	9.72e-05	178	60	4	01dafd19de04eff459253eaa9a35debf8f3deedf
ToppCell	facs-Lung-Endomucin-24m-Myeloid-myeloid_dendritic_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NUSAP1 DOCK8 POLE LARP1B	9.93e-05	179	60	4	e520eadde4f1b7fb868dbbe94c4d62b3776c55eb
ToppCell	COVID-19_Mild-gd_T\|COVID-19_Mild / Disease condition and Cell class	A2M TTC16 MATK RNF213	1.08e-04	183	60	4	f593a89b0aa8fffdfa403769916facfd30358521
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PTPRQ ROS1	1.10e-04	184	60	4	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PTPRQ ROS1	1.10e-04	184	60	4	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PTPRQ ROS1	1.10e-04	184	60	4	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	A2M EPRS1 DOCK8 RNF213	1.13e-04	185	60	4	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	Control-T_cells-CD8+_T_cells\|Control / group, cell type (main and fine annotations)	A2M CCDC88C DIP2A DOCK8	1.13e-04	185	60	4	02ab64c0166c0646d1d4c6ed110ef0b75a1096d0
ToppCell	LPS_only\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RNF213 GBP3 ATP13A3 TOP1	1.13e-04	185	60	4	a72ccb147ca505880e2da8f6a70b9d570464a691
ToppCell	mild-Lymphocytic-Plasmablast\|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	OSTC MYO1D UGT2B17 LARP1B	1.15e-04	186	60	4	060510c21b1e0889b7a6eeb15821b9e2f03a0f99
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	A2M EPRS1 DOCK8 RNF213	1.15e-04	186	60	4	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	droplet-Heart-nan-3m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PIR IL6ST	1.22e-04	189	60	4	8e583ec4df0f5b79ce5211cc99ecd8616d180bde
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M CCDC88C MATK RNF213	1.22e-04	189	60	4	0e8d1be3c406d1a393e18faccfe89116a8f82bcf
ToppCell	368C-Lymphocytic-NK_cells-Proliferating_NK_cell\|368C / Donor, Lineage, Cell class and subclass (all cells)	NUSAP1 CCDC34 ZFP69 ZNF653	1.22e-04	189	60	4	31d34bc75d4457fca197e1766922e987dbd5f8a9
ToppCell	mild-Lymphocytic-Plasmablast\|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	A2M OSTC MYO1D LARP1B	1.22e-04	189	60	4	db2097e6e165004d47ed504e115083a4e4f4b147
ToppCell	droplet-Heart-nan-3m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PIR IL6ST	1.22e-04	189	60	4	fb2253b8463d08b3d28e952a31a23dea2c2d986b
ToppCell	3'_v3-blood-Lymphocytic_T_CD8\|blood / Manually curated celltypes from each tissue	A2M DIP2A TTC16 RNF213	1.25e-04	190	60	4	5dca8654964c41580fa3b094579fe7cb296d406f
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial-Lgr5-_amplifying_undifferentiated_cell\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATP13A3 RBM28 TOP1MT PIR	1.25e-04	190	60	4	36e83995021ba16690f84e2077a9e8baec547d05
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial-epithelial_cell_of_large_intestine\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATP13A3 RBM28 TOP1MT PIR	1.25e-04	190	60	4	d26be9e1b676f750e716b91ebc3598fac3735612
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_T_CD8-Tem/emra_CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	A2M TTC16 MATK RNF213	1.25e-04	190	60	4	66d29f53f129fc18771f6214316a913eeaccd55e
ToppCell	3'_v3-blood-Lymphocytic_T_CD8-Tem/emra_CD8\|blood / Manually curated celltypes from each tissue	A2M TTC16 MATK RNF213	1.25e-04	190	60	4	5624f711b34132081f93fa70702316962e3e3c64
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CCDC88C EPRS1 BAZ1B CAT	1.27e-04	191	60	4	6e1d00404d795ec7cf60f685e42e4ad9a16ac596
ToppCell	droplet-Marrow-BM-30m-Myeloid-granulocytopoietic_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NUSAP1 CCDC34 PTDSS2 FAHD1	1.27e-04	191	60	4	08be56a4055a73c920d345fd3b2052a5ccb675d8
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CCDC88C EPRS1 BAZ1B CAT	1.27e-04	191	60	4	f158e393976b685b896a41871bda1ab65a8b58f5
ToppCell	Calu_3-infected-SARSCoV2\|infected / Cell line, Condition and Strain	UBA7 GBP2 RNF213 GBP3	1.27e-04	191	60	4	2da876d26f37a00dbdf1ee79d724306e8b20f304
ToppCell	droplet-Heart-nan-18m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PIR IL6ST	1.30e-04	192	60	4	0b9b2eaed45456d7d74ce78a64ef4a26ac2458fb
ToppCell	(210)_NKT_cell\|World / immune cells in Peripheral Blood (logTPM normalization)	CCDC88C DIP2A TTC16 MATK	1.30e-04	192	60	4	08dc0c019c594da7b9944db8fd706aa7780e6ae9
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	A2M CNBD1 DOCK8 RNF213	1.30e-04	192	60	4	935a4a36881a9fa4daa02cba96af07f6686ed8d6
ToppCell	(21)_NKT_cell\|World / immune cells in Peripheral Blood (logTPM normalization)	CCDC88C DIP2A TTC16 MATK	1.30e-04	192	60	4	b0a573ddde2978485a857b8261ee1ee5ef68ecef
ToppCell	368C-Lymphocytic-NK_cells-Proliferating_NK_cell\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	NUSAP1 CCDC34 ZFP69 ZNF653	1.33e-04	193	60	4	5f5904cec8b2967154ef2eab3c48f51df53aca4a
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_B-Plasma_cell-B_c05-MZB1-XBP1\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	OSTC EPRS1 PIGK LARP1B	1.33e-04	193	60	4	43ffa8ecc72bebcd204279db2bde98ae48d97f90
ToppCell	IIH-CD8\|IIH / Condition, Cell_class and T cell subcluster	CCDC88C TTC16 MATK RNF213	1.33e-04	193	60	4	343ac8c6dc6d7c7a944a14de65f1d4ea3dfafe86
ToppCell	IIH-CD8-CD8_1\|IIH / Condition, Cell_class and T cell subcluster	CCDC88C TTC16 MATK RNF213	1.33e-04	193	60	4	c5a4926003906d6726155f19061b73fb45d9962c
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-innate_lymphocytic\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CCDC88C DIP2A TTC16 MATK	1.35e-04	194	60	4	8bfd7c5be518b81b17913139bcb3ebea01f48dd5
ToppCell	droplet-Heart-4Chambers-21m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PIR IL6ST	1.35e-04	194	60	4	c5e77650d7abee339ec38fa78a622bb124db3fa5
ToppCell	10x5'v1-week_12-13-Lymphocytic_NK\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	TTC16 MATK GBP2 RNF213	1.35e-04	194	60	4	5afe7f48d3383f3dac18765f97999c8b6936dc1b
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_Tem\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC88C TTC16 MATK RNF213	1.35e-04	194	60	4	e72be6dc2711c1d4f16943c8615cf9dc2e961ff3
ToppCell	10x5'v1-week_12-13-Lymphocytic_NK-T_NK\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	TTC16 MATK GBP2 RNF213	1.35e-04	194	60	4	ec7e0ca6c9a2f63938e06ee771da09eff14fc3b5
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_Tem\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CCDC88C TTC16 MATK RNF213	1.35e-04	194	60	4	ac03be73fdc32dacd4a450c0fb28617e043b8444
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_Tem-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CCDC88C TTC16 MATK RNF213	1.35e-04	194	60	4	7ab4418a8a12c488d74af3676bdac672628da80c
ToppCell	COVID-19_Convalescent-PLT_4\|COVID-19_Convalescent / Disease Group and Platelet Clusters	UTP18 IRF2 TOP1 USP33	1.35e-04	194	60	4	ce1fad4e76a87f0c35e430ed1f2262395df882fd
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_Tem-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC88C TTC16 MATK RNF213	1.35e-04	194	60	4	760761ce7d22edf9a8cec71e8ab0caa273fce3f7
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-innate_lymphocytic-mature_NK_T_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CCDC88C DIP2A TTC16 MATK	1.35e-04	194	60	4	f0707601883b234ed477c7704ca9a88efaefc3fd
ToppCell	Control-CD8+_Tem\|Control / Disease condition and Cell class	A2M TTC16 MATK RNF213	1.38e-04	195	60	4	7503b3e032f95b350a2782d28e4d412a8dc9ebcc
ToppCell	COVID-19_Severe-CD8+_Tem\|COVID-19_Severe / Disease condition and Cell class	A2M TTC16 MATK RNF213	1.38e-04	195	60	4	ff7ae62393e1c858a10592db8e6d9f36b8bae396
ToppCell	droplet-Heart-4Chambers-21m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PIR IL6ST	1.38e-04	195	60	4	df644b4c3ddccd34614ece5a2378000e6bc0fa10
ToppCell	B_cells-ISG-high_B_cells\|B_cells / Immune cells in Kidney/Urine in Lupus Nephritis	GBP2 RNF213 GBP3 IRF2	1.38e-04	195	60	4	b64d9e1a8834401b4dc501566546647754ae21fc
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M CCDC88C MATK RNF213	1.38e-04	195	60	4	cab90c67a7b3119c0d0d2d5e84511c41dcb8765f
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC88C TTC16 MATK RNF213	1.41e-04	196	60	4	093fb240e72911dfd360aa6edf8ed2d611c78a1e
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M CCDC88C TTC16 MATK	1.41e-04	196	60	4	51c750a0fb2b87e17e62b984c91fb16f676d7e76
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD8+_T\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M TTC16 MATK RNF213	1.41e-04	196	60	4	0f3c7fd450aaa1f866b8558692534c0ea2a34e75
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CCDC88C TTC16 MATK RNF213	1.41e-04	196	60	4	c06caba0c91b8ee66f42bc43ec75eb2475f07056
ToppCell	droplet-Heart-nan-18m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M HMCN1 PIR IL6ST	1.41e-04	196	60	4	e386526332138e636aef2542c11316347a45689c
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD8+_T\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	A2M TTC16 MATK RNF213	1.41e-04	196	60	4	4e1f8828413896ab8a4ec92a89d6789e8e37e05a
ToppCell	10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-Stress_sig-Z\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CCDC88C TTC16 MATK RNF213	1.41e-04	196	60	4	578afe58962a24874b99b0407a647b12e972344b
Drug	acridine	POLE POLG UGT2B15 UGT2B17 TOP1MT TOP1	6.51e-08	81	59	6	CID000009215
Drug	MS-222	UGT2B15 UGT2B17 CAT TOP1	5.11e-06	44	59	4	CID000011400
Drug	CI-937	CAT TOP1MT TOP1	5.90e-06	14	59	3	CID005364123
Drug	Topotecan	TOP1MT TOP1	6.60e-06	2	59	2	DB01030
Drug	Irinotecan	TOP1MT TOP1	6.60e-06	2	59	2	DB00762
Drug	lurtotecan	UBA7 TOP1MT TOP1	7.36e-06	15	59	3	CID000060955
Drug	2-chloro-dATP	POLE TOP1MT TOP1	1.10e-05	17	59	3	CID000122644
Drug	BrdUTP	POLG GAST TOP1	1.10e-05	17	59	3	CID000065267
Drug	AC1MHQTP	CAT TOP1MT TOP1	1.31e-05	18	59	3	CID003009741
Drug	SN-38G	UGT2B15 UGT2B17 TOP1MT TOP1	1.66e-05	59	59	4	CID000443154
Drug	plakinidine A	TOP1MT TOP1	1.98e-05	3	59	2	CID005468016
Drug	N-ethylethylenediamine	TOP1MT TOP1	1.98e-05	3	59	2	CID000066071
Drug	perylenediimide	TOP1MT TOP1	1.98e-05	3	59	2	CID000066475
Drug	chavibetol	TOP1MT TOP1	1.98e-05	3	59	2	CID000596375
Drug	2,2,5,5-tetramethylimidazolidin-4-one	TOP1MT TOP1	1.98e-05	3	59	2	CID009812798
Drug	v 2182	TOP1MT TOP1	1.98e-05	3	59	2	CID000078632
Drug	G-Gly 7	CAT GAST	1.98e-05	3	59	2	CID000130039
Drug	AC1L1KJQ	MATK CAT GAST	3.22e-05	24	59	3	CID000005529
Drug	Hymecromone	UGT2B15 UGT2B17 CAT	3.65e-05	25	59	3	ctd:D006923
Drug	oxophoebine	TOP1MT TOP1	3.95e-05	4	59	2	CID000159317
Drug	lauterine	TOP1MT TOP1	3.95e-05	4	59	2	CID000073104
Drug	4-hydroxymethyl-4',5'-benzopsoralen	TOP1MT TOP1	3.95e-05	4	59	2	CID000147789
Drug	indole-4,7-dione	TOP1MT TOP1	3.95e-05	4	59	2	CID000152300
Drug	methylphenylcarbamate	TOP1MT TOP1	3.95e-05	4	59	2	CID000017451
Drug	mitindomide	TOP1MT TOP1	3.95e-05	4	59	2	CID000066362
Drug	pMTT	TOP1MT TOP1	3.95e-05	4	59	2	CID005276916
Drug	2-fluoro-dATP	TOP1MT TOP1	3.95e-05	4	59	2	CID000126365
Drug	dioxazine	TOP1MT TOP1	3.95e-05	4	59	2	CID011969523
Drug	3-O-alpha-L-arabinopyranosyl-oleanolic acid	TOP1MT TOP1	3.95e-05	4	59	2	CID000124369
Drug	A-74932	TOP1MT TOP1	3.95e-05	4	59	2	CID000132825
Drug	20,29-dihydrobetulinic acid	TOP1MT TOP1	3.95e-05	4	59	2	CID000065319
Drug	tumulosic acid	TOP1MT TOP1	3.95e-05	4	59	2	CID005322174
Drug	NSC 380271	TOP1MT TOP1	3.95e-05	4	59	2	CID000342690
Drug	dFdCTP	POLE POLG TOP1	4.63e-05	27	59	3	CID000130659
Drug	spermidine	POLE POLG CAT GAST TOP1MT TOP1	4.88e-05	253	59	6	CID000001102
Drug	AC1Q5O3Q	UBA7 TOP1MT TOP1	5.76e-05	29	59	3	CID000368335
Drug	NSC 314622	TOP1MT TOP1	6.57e-05	5	59	2	CID000329826
Drug	L-dopa melanin	TOP1MT TOP1	6.57e-05	5	59	2	CID000124595
Drug	2-bromo-dATP	TOP1MT TOP1	6.57e-05	5	59	2	CID000129443
Drug	3aH-benzimidazole	TOP1MT TOP1	6.57e-05	5	59	2	CID009548683
Drug	11-deoxydaunorubicin	TOP1MT TOP1	6.57e-05	5	59	2	CID000158483
Drug	4-demethoxy-11-deoxy-4'-epi-daunorubicin	TOP1MT TOP1	6.57e-05	5	59	2	CID000158476
Drug	mucronulatol	TOP1MT TOP1	6.57e-05	5	59	2	CID000442811
Drug	coralyne	DAG1 TOP1	6.57e-05	5	59	2	CID000023306
Drug	AC1L43MI	TOP1MT TOP1	6.57e-05	5	59	2	CID000150081
Drug	NSC622082	TOP1MT TOP1	6.57e-05	5	59	2	CID000494392
Drug	elomotecan	TOP1MT TOP1	6.57e-05	5	59	2	CID000216300
Drug	40 r.p	CAT GAST	6.57e-05	5	59	2	CID000164685
Drug	4-demethyl-6-O-methyldoxorubicin	TOP1MT TOP1	6.57e-05	5	59	2	CID000126902
Drug	eupolauridine	TOP1MT TOP1	6.57e-05	5	59	2	CID000072486
Drug	al-Badry	UGT2B15 UGT2B17 CAT TOP1MT TOP1	6.87e-05	165	59	5	CID000004545
Drug	ddTTP	POLE POLG DAG1 CAT	7.37e-05	86	59	4	CID000065051
Drug	menthol	UGT2B15 UGT2B17 TOP1MT TOP1	7.71e-05	87	59	4	CID000001254
Drug	AC1L191M	DAG1 CAT TOP1MT TOP1	8.42e-05	89	59	4	CID000000350
Drug	hydroxyphenylacetic acid	MATK UGT2B15 UGT2B17	8.53e-05	33	59	3	CID000011970
Drug	AC1L8YYB	UBA7 TOP1MT TOP1	9.34e-05	34	59	3	CID000435167
Drug	intoplicine	TOP1MT TOP1	9.84e-05	6	59	2	CID000065954
Drug	Chk2 inhibitor	TOP1MT TOP1	9.84e-05	6	59	2	CID009882612
Drug	DMP 840	TOP1MT TOP1	9.84e-05	6	59	2	CID000060916
Drug	BE-10988	TOP1MT TOP1	9.84e-05	6	59	2	CID000126200
Drug	galbacin	TOP1MT TOP1	9.84e-05	6	59	2	CID000234441
Drug	lorcaserin	UGT2B15 UGT2B17	9.84e-05	6	59	2	ctd:C506658
Drug	Arg-Trp	CAT GAST	9.84e-05	6	59	2	CID006426951
Drug	UCE6	TOP1MT TOP1	9.84e-05	6	59	2	CID000127735
Drug	dFdCMP	POLE POLG	9.84e-05	6	59	2	CID000503015
Drug	ethoxidine	TOP1MT TOP1	9.84e-05	6	59	2	CID000476777
Drug	berberrubine	TOP1MT TOP1	9.84e-05	6	59	2	CID000072703
Drug	saintopin	TOP1MT TOP1	9.84e-05	6	59	2	CID000131350
Drug	aminocatechol	TOP1MT TOP1	9.84e-05	6	59	2	CID000151726
Drug	NBQCl	TOP1MT TOP1	1.37e-04	7	59	2	CID000134086
Drug	D01432	TOP1MT TOP1	1.37e-04	7	59	2	CID011954228
Drug	nitidine	TOP1MT TOP1	1.37e-04	7	59	2	CID000004501
Drug	AC1L1SSP	DAG1 CAT	1.37e-04	7	59	2	CID000009316
Drug	AC1NSKN6	PKD2L1 TOP1	1.37e-04	7	59	2	CID005311441
Drug	AC1L4GCF	TOP1MT TOP1	1.37e-04	7	59	2	CID000156514
Drug	Cycloheximide	MYO1D PIGK DAG1 UGT2B15 CAT IRS1 IL6ST	1.50e-04	446	59	7	ctd:D003513
Drug	10-hydroxycamptothecin	UBA7 TOP1MT TOP1	1.53e-04	40	59	3	CID000097226
Drug	virginiamycin complex	CAT ROS1 PIR	1.53e-04	40	59	3	CID000005674
Drug	Sulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	CCDC88C POLG BAZ1B GBP2 IL6ST	1.62e-04	198	59	5	4733_DN
Drug	Laudanosine (R,S) [1699-51-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A	DIP2A POLG DAG1 PTDSS2 ATP13A3	1.66e-04	199	59	5	7030_DN
Drug	9-HME	TOP1MT TOP1	1.83e-04	8	59	2	CID003034753
Drug	AC1NR0UN	TOP1MT TOP1	1.83e-04	8	59	2	CID005282807
Drug	Bis-netropsin	TOP1MT TOP1	1.83e-04	8	59	2	CID000482856
Drug	NSC-294410	TOP1MT TOP1	1.83e-04	8	59	2	CID000457914
Drug	T-C-T	SPG7 DAG1 TOP1MT TOP1	2.12e-04	113	59	4	CID000447409
Drug	oxolinic acid	CAT TOP1MT TOP1	2.17e-04	45	59	3	CID000004628
Drug	ardisin	TOP1MT TOP1	2.35e-04	9	59	2	CID000417291
Drug	D03954	TOP1MT TOP1	2.35e-04	9	59	2	CID009851821
Drug	un-7	ROS1 IRS1	2.35e-04	9	59	2	CID005327158
Drug	IST-622	TOP1MT TOP1	2.35e-04	9	59	2	CID003081749
Drug	o-AMSA	TOP1MT TOP1	2.35e-04	9	59	2	CID000107747
Drug	captan	POLE POLG CAT	2.47e-04	47	59	3	CID000008606
Drug	diospyrin	TOP1MT TOP1	2.93e-04	10	59	2	CID000308140
Drug	Gastrin hexapeptide	CAT GAST	2.93e-04	10	59	2	CID000189058
Drug	Edotecarinum	TOP1MT TOP1	2.93e-04	10	59	2	CID000151078
Drug	oxfendazole	DAG1 GAST	2.93e-04	10	59	2	CID000040854
Drug	1 CI	A2M IL6ST	2.93e-04	10	59	2	CID000142859
Drug	AC1MZ4R5	TOP1MT TOP1	2.93e-04	10	59	2	CID003842392
Drug	8-oxo-dGTP	POLG DAG1 CAT	2.97e-04	50	59	3	CID000107902
Drug	scopoletin	UGT2B15 UGT2B17 CAT	2.97e-04	50	59	3	CID005280460
Disease	cholic acid glucuronide measurement	UGT2B15 UGT2B17	1.18e-05	3	59	2	EFO_0800574
Disease	X-25937 measurement	UGT2B15 UGT2B17	2.35e-05	4	59	2	EFO_0800937
Disease	X-24574 measurement	UGT2B15 UGT2B17	8.20e-05	7	59	2	EFO_0800897
Disease	Williams Syndrome	BAZ1B GTF2IRD1	1.09e-04	8	59	2	C0175702
Disease	deoxycholic acid glucuronide measurement	UGT2B15 UGT2B17	1.09e-04	8	59	2	EFO_0800575
Disease	4-androsten-3alpha,17alpha-diol monosulfate (3) measurement	UGT2B15 UGT2B17	1.75e-04	10	59	2	EFO_0022090
Disease	DNA repair protein RAD51 homolog 4 measurement	UGT2B15 UGT2B17	2.14e-04	11	59	2	EFO_0801531
Disease	5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement	UGT2B15 UGT2B17	2.56e-04	12	59	2	EFO_0800291
Disease	androstenediol (3alpha, 17alpha) monosulfate (3) measurement	UGT2B15 UGT2B17	3.02e-04	13	59	2	EFO_0800293
Disease	X-19141 measurement	UGT2B15 UGT2B17	3.02e-04	13	59	2	EFO_0800799
Disease	5alpha-androstan-3alpha,17alpha-diol monosulfate measurement	UGT2B15 UGT2B17	3.52e-04	14	59	2	EFO_0800283
Disease	Williams-Beuren syndrome (implicated_via_orthology)	BAZ1B GTF2IRD1	4.06e-04	15	59	2	DOID:1928 (implicated_via_orthology)
Disease	5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement	UGT2B15 UGT2B17	5.89e-04	18	59	2	EFO_0800288
Disease	etiocholanolone glucuronide measurement	UGT2B15 UGT2B17	6.58e-04	19	59	2	EFO_0800362
Disease	androsterone glucuronide measurement	UGT2B15 UGT2B17	7.30e-04	20	59	2	EFO_0800317
Disease	Reperfusion Injury	CAT GAST IL6ST	7.63e-04	89	59	3	C0035126
Disease	X-24947 measurement	UGT2B15 UGT2B17	8.85e-04	22	59	2	EFO_0800910
Disease	Adenocarcinoma of large intestine	MATK POLE ROS1	9.51e-04	96	59	3	C1319315
Disease	epiandrosterone sulfate measurement	UGT2B15 UGT2B17	1.14e-03	25	59	2	EFO_0021120
Disease	Child Development Disorders, Specific	CNTN4 DOCK8	1.54e-03	29	59	2	C0085997
Disease	Child Development Deviations	CNTN4 DOCK8	1.54e-03	29	59	2	C0085996
Disease	Developmental Disabilities	CNTN4 DOCK8	1.65e-03	30	59	2	C0008073
Disease	Diabetes Mellitus	CAT IRS1	1.88e-03	32	59	2	C0011849
Disease	androsterone sulfate measurement	UGT2B15 UGT2B17	1.99e-03	33	59	2	EFO_0021117

Protein segments in the cluster

Peptide	Gene	Start	Entry
KVWPHKDYPLIPVGK	CAT	301	P04040
WHLKGNPDKGKPVEP	ALKBH8	596	Q96BT7
ALPPKDGKVAKINWH	ATP13A3	776	Q9H7F0
KKGERKWAPPKFLPH	BAZ1B	206	Q9UIG0
EVKGNPKPHIRWKLN	CNTN4	51	Q8IWV2
QPGVHEEPVLKKWPK	C22orf31	271	O95567
LDPGWNPQIPEKKGK	ACBD6	121	Q9BR61
VHWERPQKPKAPVGH	A2M	1181	P01023
KKGKPEPNHEWTLLA	ADAT1	21	Q9BUB4
PVHPKKPKPQINQWK	RBM28	691	Q9NW13
NLKLKKPPWLHMPSA	OSTC	16	Q9NRP0
QPGVDKPDPKTWKAN	IRF2	66	P14316
LPVKWTAPEALKHGK	MATK	386	P42679
GWHIANKKPPLPKRV	DAG1	296	Q14118
DPPPKKKNHWIGAKA	CCDC88C	1396	Q9P219
LDPGAKHSQPIPKGW	PIR	176	O00625
LWIAAKQGKHKVQPP	POLG	311	P54098
HQAGLAKVIPPKEWK	KDM4E	41	B2RXH2
AWFQQKPGKVPKHLI	IGKV1D-17	56	A0A075B6S4
KGIWMWCVPHPKKPE	GBP2	76	P32456
KGIWMWCVPHPKKPE	GBP3	76	Q9H0R5
PDPHKLKLWLKVNGE	FAHD1	141	Q6P587
NPVPRVKHPDWLHKK	POLE	1156	Q07864
RPLNYEPHKGKLKPW	NUSAP1	366	Q9BXS6
PGPAFKEVWQVILKP	IRS1	156	P35568
HQKPKLKDWHPPGGF	PIGK	356	Q92643
TWLKDGHPLLKKPGL	HMCN1	2136	Q96RW7
TGIPPPTIAWLKNHK	HMCN1	3176	Q96RW7
LKWSPPEKPNGIIIA	PTPRQ	726	Q9UMZ3
PHLVADPSKKQGPWL	GAST	66	P01350
LIKKHIWPNVPDPSK	IL6ST	646	P40189
PLQNPPIKWAEGHKG	DOCK8	706	Q8NF50
WKPIHMPPPKEAKDL	CCDC34	321	Q96HJ3
QNGIKVVKWIHNKPP	MARF1	1066	Q9Y4F3
PFQGKPKPQAIWTHD	MYBPHL	76	A2RUH7
IDGKHLAKPPKDWHP	DIP2A	486	Q14689
PPWKDPEAEHPKKVQ	GTF2IRD1	91	Q9UHL9
VPAPKVPIKMQVKHW	PRAP1	21	Q96NZ9
PWIEVKKRHQPAPVK	LARP1B	371	Q659C4
KGNFPPQKKPVWVDE	UTP18	131	Q9Y5J1
AKHPKNPEVGLKPVW	EPRS1	531	P07814
DPKPHKKLGPQAWLV	PTDSS2	371	Q9BVG9
EIWNPDSKKTKKHPP	CCT8L2	531	Q96SF2
PHGPKKMIAPQRWID	SPG7	751	Q9UQ90
ALLKWKKFPPGHVIV	CNBD1	336	Q8NA66
SKPGRPHQWVFPKDV	RNF213	4296	Q63HN8
SGRHGKPWEQVPKKP	ZNF653	96	Q96CK0
PKKAVSPVSPLQHWP	SPATA31A1	1311	Q5TZJ5
NKALEVWSVGPPLKP	UBA7	791	P41226
SKIPEPPAGHQWKEV	TOP1MT	226	Q969P6
EHLPPGKEIWGKTKN	ROS1	1541	P08922
PSPGVKEQAIWKHPQ	PKD2L1	746	Q9P0L9
KEQAIWKHPQPAPAV	PKD2L1	751	Q9P0L9
KKNEKPPKPSLHAWP	VSTM1	21	Q6UX27
DNPHKQKAWKIYPPE	TPTE2P1	51	Q5T6R2
KPWVIPAPKGILQHI	TTC16	21	Q8NEE8
KWLPQNDLLGHPKTK	UGT2B15	356	P54855
KWKFLEHKGPVFAPP	TOP1	216	P11387
LWPGLAPPHKKAQSA	USP33	446	Q8TEY7
KWLPQNDLLGHPKTK	UGT2B17	356	O75795
WVKLQHPKKAVEGAP	ZFP69	16	Q49AA0
YGKHVKWPSPPKVLR	MYO1D	756	O94832